Salarius Pharmaceuticals Inc [NASDAQ: SLRX] surged by $0.26 during the normal trading session on Tuesday and reaching a high of $2.31 during the day while it closed the day at $1.0.
Salarius Pharmaceuticals Inc stock has also gained 40.75% of its value over the past 7 days. However, SLRX stock has inclined by 43.21% in the 3 months of the year. Over the past six months meanwhile, it has lost -59.37% and lost -71.44% year-on date.
The market cap for SLRX stock reached $2.13 million, with 2.13 million shares outstanding and 2.11 million shares in the current float. Compared to the average trading volume of 1.28M shares, SLRX reached a trading volume of 92314655 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Salarius Pharmaceuticals Inc [SLRX]:
Ladenburg Thalmann have made an estimate for Salarius Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 27, 2020.
The Price to Book ratio for the last quarter was 33.63, with the Price to Cash per share for the same quarter was set at 0.84.
SLRX stock trade performance evaluation
Salarius Pharmaceuticals Inc [SLRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 40.75. With this latest performance, SLRX shares gained by 0.98% in over the last four-week period, additionally sinking by -59.37% over the last 6 months – not to mention a drop of -45.67% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SLRX stock in for the last two-week period is set at 65.35, with the RSI for the last a single of trading hit 0.2556, and the three-weeks RSI is set at 0.1729 for Salarius Pharmaceuticals Inc [SLRX]. The present Moving Average for the last 50 days of trading for this stock 0.8120, while it was recorded at 0.7884 for the last single week of trading, and 1.2473 for the last 200 days.
Salarius Pharmaceuticals Inc (SLRX) Capital Structure & Debt Analysis
According to recent financial data for Salarius Pharmaceuticals Inc. ( SLRX), the Return on Equity (ROE) stands at -300.16%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -154.23%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Salarius Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -9003.36%, showcasing its effectiveness in deploying capital for earnings.
Salarius Pharmaceuticals Inc (SLRX) Efficiency & Liquidity Metrics
Based on Salarius Pharmaceuticals Inc’s (SLRX) latest financial statements, the Debt-to-Equity Ratio is 1.83%, indicating its reliance on debt financing relative to shareholder equity.
Salarius Pharmaceuticals Inc (SLRX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Salarius Pharmaceuticals Inc. (SLRX) effectively leverages its workforce, generating an average of -$2785000.0 per employee. The company’s liquidity position is robust, with a Current Ratio of 0.89% and a Quick Ratio of 0.89%, indicating strong ability to cover short-term liabilities.
Salarius Pharmaceuticals Inc [SLRX]: Institutional Ownership
There are presently around $6.57%, or 6.69% of SLRX stock, in the hands of institutional investors.
